Evaluation of 111In-Labeled Cyclic RGD Peptides: Tetrameric not Tetravalent
Authors:
- 13 April 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 21 (5) , 969-978
Abstract
This report presents the synthesis and evaluation of 111In(DOTA-6G-RGD4) (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid; 6G-RGD4 = E{G3-E[G3-c(RGDfK)]2}2 and G3 = Gly-Gly-Gly), 111In(DOTA-RGD4) (RGD4 = E{E[c(RGDfK)]2}2) and 111In(DOTA-3G-RGD2) (3G-RGD2 = G3-E[G3-c(RGDfK)]2) as new radiotracers for imaging integrin αvβ3-positive tumors. The IC50 values of DOTA-6G-RGD4, DOTA-RGD4, and DOTA-3G-RGD2 were determined to be 0.4 ± 0.1, 1.4 ± 0.1 and 1.1 ± 0.1 nM against 125I-c(RGDyK) bound to integrin αvβ3-positive U87MG human glioma cells. 111In(DOTA-6G-RGD4), 111In(DOTA-RGD4), and 111In(DOTA-3G-RGD2) were prepared by reacting 111InCl3 with the respective DOTA conjugate in NH4OAc buffer (100 mM, pH = 5.5). Radiolabeling could be completed by heating the reaction mixture at 100 °C for 15−20 min. The specific activity was ∼1850 MBq/μmol for 111In(DOTA-3G-RGD2) and ∼1480 MBq/μmol for 111In(DOTA-6G-RGD4). The athymic nude mice bearing U87MG human glioma xenografts were used to evaluate tumor uptake and excretion kinetics of 111In(DOTA-6G-RGD4), 111In(DOTA-RGD4), and 111In(DOTA-3G-RGD2). The results from both the integrin αvβ3 binding assay and biodistribution studies suggest that the tetrameric cyclic RGD peptides, such as RGD4 and 6G-RGD4, are most likely bivalent in binding to the integrin αvβ3. Both 111In(DOTA-6G-RGD4) and 111In(DOTA-RGD4) had significantly higher tumor uptake than 111In(DOTA-3G-RGD2) at 24−72 h postinjection due to the extra RGD motifs in RGD4 and 6G-RGD4. 111In(DOTA-3G-RGD2) had very little metabolism, while 111In(DOTA-6G-RGD4) had significant metabolism during its excretion via both renal and hepatobiliary routes over the 2 h period, probably due to its much larger size. The combination of high tumor uptake with long tumor retention suggests that their corresponding 90Y and 177Lu analogues M(DOTA-6G-RGD4) (M = 90Y and 177Lu) might be useful as therapeutic radiotracers for treatment of integrin αvβ3-positive solid tumors.Keywords
This publication has 40 references indexed in Scilit:
- Radiolabeled Cyclic RGD Peptides as Integrin αvβ3-Targeted Radiotracers: Maximizing Binding Affinity via BivalencyBioconjugate Chemistry, 2009
- 2-Mercaptoacetylglycylglycyl (MAG2) as a Bifunctional Chelator for 99mTc-Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and PharmacokineticsBioconjugate Chemistry, 2009
- Improving Tumor Uptake and Pharmacokinetics of 64Cu-Labeled Cyclic RGD Peptide Dimers with Gly3 and PEG4 LinkersBioconjugate Chemistry, 2009
- Improving Tumor-Targeting Capability and Pharmacokinetics of 99mTc-Labeled Cyclic RGD Dimers with PEG4 LinkersMolecular Pharmaceutics, 2008
- Improving Tumor Uptake and Excretion Kinetics of 99mTc-Labeled Cyclic Arginine-Glycine-Aspartic (RGD) Dimers with Triglycine LinkersJournal of Medicinal Chemistry, 2008
- Coligand effects on the solution stability, biodistribution and metabolism of the 99mTc-labeled cyclic RGDfK tetramerNuclear Medicine and Biology, 2008
- Linker Effects on Biological Properties of 111In-Labeled DTPA Conjugates of a Cyclic RGDfK DimerBioconjugate Chemistry, 2007
- Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptideNuclear Medicine and Biology, 2007
- Impact of PKM Linkers on Biodistribution Characteristics of the 99mTc-Labeled Cyclic RGDfK DimerBioconjugate Chemistry, 2006
- Micro-PET Imaging of αvβ3-Integrin Expression with 18F-Labeled Dimeric RGD PeptideMolecular Imaging, 2004